Tenvir Em Tablet (Emtricitabine (200mg) and Tenofovir Disoproxil Fumarate (300mg))

Tenvir Em Tablet is a combination of two antiviral medicines, such as emtricitabine and tenofovir disoproxil fumarate. It is prescribed to treat HIV (human immunodeficiency virus) infection. This medicine effectively prevents the virus from multiplying, thereby reducing the viral load in the body.

It also increases the CD4 cell count in the body so that your immune system can work better. This medicine helps to improve the life span and reduce the other complications during the infection. It can be used alone or in combination with other medicine.

HIV

Side effects are undesirable symptoms that can result from any medical treatment. Like any other medicine, Tenvir Em Tablet (Emtricitabine 200mg and Tenofovir Disoproxil Fumarate 300mg) also causes some adverse impact on the body, most of which resolves without any medical attention. However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.​

Some common side effects include:
● Nausea
● Diarrhea
● Headache
● Depression
● Rash
● Dizziness
● Fatigue
● Vomiting
● Insomnia (difficulty sleeping)
● Weakness
● Abnormal dreams
● Abdominal pain
● Weight loss

The doctor determines the dosage and duration of Tenvir Em Tablet (Emtricitabine 200mg and Tenofovir Disoproxil Fumarate 300mg) as per the severity of infection as well as age & overall health condition of the patients. Swallow it as a whole with water, and don't chew, crush, or break the tablet.

This tablet may be taken with or without food. In case of an overdose of this tablet, contact your doctor or any healthcare provider and seek medical attention immediately.

● DeJesus, E., Ramgopal, M., Crofoot, G., Ruane, P., LaMarca, A., Mills, A., ... & Cao, H. (2017). Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. The Lancet HIV, 4(5), e205-e213.
● Kabbara, W. K., & Ramadan, W. H. (2015). Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults. Journal of infection and public health, 8(5), 409-417.
● Avihingsanon, A., Lu, H., Leong, C. L., Hung, C. C., Koenig, E., Kiertiburanakul, S., ... & Li, T. (2023). Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. The Lancet HIV, 10(10), e640-e652.
● Ogbuagu, O., Ruane, P. J., Podzamczer, D., Salazar, L. C., Henry, K., Asmuth, D. M., ... & Young, B. (2021). Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. The lancet HIV, 8(7), e397-e407.
● Lockman, S., Brummel, S. S., Ziemba, L., Stranix-Chibanda, L., McCarthy, K., Coletti, A., ... & Whalen, F. (2021). Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet, 397(10281), 1276-1292.